Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fusidic Acid 1% for Suspected Bacterial Conjunctivitis
NCT06911424Phase 3Recruiting
- Sponsor
- Baxis Pharmaceuticals
- Start
- Mar 2025
- Primary completion
- Mar 2026
- Modality
- Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in bacterial conjunctivitis (BC) comparing Fusidic Acid 1% with Placebo (2 arms). Primary endpoint: Clinical Cure at Day 4. Started Mar 2025; status: recruiting.
02
Drugs
fusidic acid
03
Conditions
bacterial conjunctivitis (BC)
Beyond the preview
Go deeper on NCT06911424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06911424.